These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37254309)

  • 1. Structure-guided identification of potent inhibitors of ROS1 kinase for therapeutic development against non-small cell lung cancer.
    Khan MS; Altwaijry N; Al-Bagmi MS; Alafaleq NO; Alokail MS; Shahwan M; Shamsi A
    J Biomol Struct Dyn; 2024 May; 42(8):3837-3847. PubMed ID: 37254309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacophore based virtual screening, molecular docking and molecular dynamic simulation studies for finding ROS1 kinase inhibitors as potential drug molecules.
    Vanajothi R; Vedagiri H; Al-Ansari MM; Al-Humaid LA; Kumpati P
    J Biomol Struct Dyn; 2022 May; 40(8):3385-3399. PubMed ID: 33200682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Insights into the Molecular Design of ROS1 Inhibitor for the Treatment of Non-Small Cell Lung Cancer (NSCLC).
    Adhikary R; Khandelwal R; Hussain T; Nayarisseri A; Singh SK
    Curr Comput Aided Drug Des; 2021; 17(3):387-401. PubMed ID: 32364080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution strategy of ROS1 kinase inhibitors for use in cancer therapy.
    Liu S; Yang H; Jiang Y; Zhang T; Yan R; Zhang J
    Future Med Chem; 2018 Jul; 10(14):1705-1720. PubMed ID: 29961337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.
    Chin LP; Soo RA; Soong R; Ou SH
    J Thorac Oncol; 2012 Nov; 7(11):1625-30. PubMed ID: 23070242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a first-in-class protein degrader for the c-ros oncogene 1 (ROS1).
    Yang J; Wu Y; Zhu Q; Qu X; Ou H; Liu H; Wei Y; Ge D; Lu C; Jiang B; Song X
    Bioorg Chem; 2024 Sep; 150():107590. PubMed ID: 38955003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations.
    Wu X; Wang Y; Wan S; Zhang J
    J Biomol Struct Dyn; 2018 Sep; 36(12):3106-3113. PubMed ID: 28893136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
    Davare MA; Vellore NA; Wagner JP; Eide CA; Goodman JR; Drilon A; Deininger MW; O'Hare T; Druker BJ
    Proc Natl Acad Sci U S A; 2015 Sep; 112(39):E5381-90. PubMed ID: 26372962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK.
    Tian Y; Yu Y; Shen Y; Wan H; Chang S; Zhang T; Wan S; Zhang J
    J Chem Inf Model; 2017 Apr; 57(4):977-987. PubMed ID: 28318251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based optimization and biological evaluation of trisubstituted pyrazole as a core structure of potent ROS1 kinase inhibitors.
    Park BS; Al-Sanea MM; Abdelazem AZ; Park HM; Roh EJ; Park HM; Yoo KH; Sim T; Tae JS; Lee SH
    Bioorg Med Chem; 2014 Aug; 22(15):3871-8. PubMed ID: 24997577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
    Frampton JE
    Drugs; 2021 Apr; 81(6):697-708. PubMed ID: 33871816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel
    Elasbali AM; Al-Soud WA; Elfaki EM; Alanazi HH; Alharbi B; Alharethi SH; Anwer K; Mohammad T; Hassan MI
    J Biomol Struct Dyn; 2024 Jul; 42(11):5982-5994. PubMed ID: 37403288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ROS1 Kinase Inhibitors for Molecular-Targeted Therapies.
    Al-Sanea MM; Abdelazem AZ; Park BS; Yoo KH; Sim T; Kwon YJ; Lee SH
    Curr Med Chem; 2016; 23(2):142-60. PubMed ID: 26438251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
    Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
    Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
    Morris TA; Khoo C; Solomon BJ
    Drugs; 2019 Aug; 79(12):1277-1286. PubMed ID: 31313100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
    Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore-based designing of putative ROS-1 targeting agents for NSCLC.
    Pathak D; Choudhary S; Singh PK; Singh M; Chadha N; Silakari O
    Mol Divers; 2021 May; 25(2):1091-1102. PubMed ID: 32002714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Flavonoids as Putative ROS-1 Kinase Inhibitors Using Pharmacophore Modeling for NSCLC Therapeutics.
    Parate S; Kumar V; Hong JC; Lee KW
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33917039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.